<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470832</url>
  </required_header>
  <id_info>
    <org_study_id>WP29402</org_study_id>
    <secondary_id>2015-000261-31</secondary_id>
    <nct_id>NCT02470832</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      The study is being conducted to investigate the effect of itraconazole treatment in the
      pharmacokinetics of RG1662. It is also to evaluate the exposure of RG1662 vs. QTc response
      relationship and the safety and tolerability of RG1662 when given in combination with
      itraconazole in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from 0-t (AUC0-t)</measure>
    <time_frame>Within 29 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Within 29 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Within 29 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in QTcF</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Within 43 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in physical examination or laboratory parameters</measure>
    <time_frame>Within 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean model parameters of RG1662 concentration vs. QTcF changes</measure>
    <time_frame>Within 29 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Patient Study</condition>
  <arm_group>
    <arm_group_label>Combination therapy RG1662 + itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 20-29: Oral administration RG1662 twice daily within 30 minutes of a meal + 2 x 100 mg itraconazole once daily with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RG1662 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1-10: RG1662 120 mg twice daily (b.i.d.) within 30 minutes of a meal for 10 days (Days 1 to 9, Day 10 only a.m. dose). (Cohort A subjects will receive 1 x 120 mg RG1662 tablets twice daily. In Cohorts B and C the dose of RG1662 will be decided upon following review of the interim safety and pharmacokinetic data of the 4 subjects in Cohort A.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>itraconazole Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 15-19: 200 mg of itraconazole twice daily for 5 days (Days 15 to 18, Day 19 only a.m. dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RG1662</intervention_name>
    <arm_group_label>Combination therapy RG1662 + itraconazole</arm_group_label>
    <arm_group_label>RG1662 Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <arm_group_label>Combination therapy RG1662 + itraconazole</arm_group_label>
    <arm_group_label>itraconazole Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female volunteers

          -  Ages 18 to 60 years, inclusive

          -  A body mass index (BMI) between 18 to 32 kg/m2, inclusive

          -  Agreement to comply with study restrictions

        Exclusion Criteria:

          -  History of epilepsy, convulsions or significant head injury or electroencephalogram
             (EEG) abnormalities

          -  Electrocardiogram (EGC) or vital signs abnormalities

          -  Significant history of drug allergy, as determined by the Investigator, or a known
             hypersensitivity to any of the ingredients of any of the study treatments

          -  Use of any drugs or substances that are known to be substrates, inducers or inhibitors
             of CYP3A4 within 30 days of the first dose administration

          -  Pregnant or lactating

          -  Any other clinically relevant abnormalities, concomitant diseases or ongoing medical
             conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

